July 23, 2016 5:53 AM ET


Company Overview of Rigel Pharmaceuticals, Inc.

Company Overview

Rigel Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology. It is developing fostamatinib, an oral spleen tyrosine kinase inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and in Phase II clinical trials for autoimmune hemolytic anemia and IgA nephropathy; R348, an ophthalmic janus kinase/spleen tyrosine kinase inhibitor that is in Phase II clinical trials for the treatment of patients with ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has li...

1180 Veterans Boulevard

South San Francisco, CA 94080

United States

Founded in 1996

126 Employees





Key Executives for Rigel Pharmaceuticals, Inc.

Chief Executive Officer, President, Director and Member of Finance Committee
Age: 55
Total Annual Compensation: $600.0K
Co-Founder, President of Discovery & Research, Executive Vice President and Director
Age: 67
Total Annual Compensation: $559.6K
Chief Financial Officer and Executive Vice President
Age: 47
Total Annual Compensation: $441.3K
Executive Vice President of Corporate Affairs, General Counsel and Corporate Secretary
Age: 51
Total Annual Compensation: $475.5K
Age: 68
Total Annual Compensation: $521.3K
Compensation as of Fiscal Year 2015.

Rigel Pharmaceuticals, Inc. Key Developments

Rigel Pharmaceuticals, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 10:30 AM

Rigel Pharmaceuticals, Inc. Presents at Jefferies 2016 Healthcare Conference, Jun-09-2016 10:30 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Ryan D. Maynard, Chief Financial Officer and Executive Vice President.

Rigel Pharmaceuticals, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016

Rigel Pharmaceuticals, Inc. reported unaudited earnings results for the first quarter ended March 31, 2016. For the quarter, the company reported contract revenues from collaborations of $5,029,000 compared to $2,178,000 a year ago. Loss from operations was $17,567,000 compared to $18,241,000 a year ago. Net loss was $17,464,000 or $0.19 per basic and diluted share compared to $18,193,000 or $0.21 per basic and diluted share a year ago.

Rigel Pharmaceuticals, Inc. to Report Q1, 2016 Results on May 03, 2016

Rigel Pharmaceuticals, Inc. announced that they will report Q1, 2016 results at 5:00 PM, Eastern Standard Time on May 03, 2016

Similar Private Companies By Industry

Company Name Region
20n Labs, Inc. United States
23andMe, Inc. United States
2C Tech Corporation, Inc. United States
3-V Biosciences, Inc. United States
3D Bio Holdings LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rigel Pharmaceuticals, Inc., please visit www.rigel.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.